Partner
Chiaki Kobayashi is the managing partner of Finnegan’s Tokyo office. She practices all aspects of intellectual property (IP) law, including client counseling, prosecution, opinion preparation, due diligence investigations, litigation, and post-grant review proceedings, with a focus on the chemical, biotechnology, and pharmaceutical industries.
With her fluency in Japanese and deep cultural appreciation, Chiaki has significant experience counseling Japanese clients on strategic IP development, patent portfolio management, due diligence, patent prosecution, litigation, and pre-litigation strategies. She has extensive experience with litigation involving Japanese parties, and she routinely works with in-house counsel and vendors to smooth the process of U.S. litigation for Japanese clients.
Chiaki’s litigation practice includes numerous aspects of patent disputes, including coordinating discovery; developing infringement and invalidity strategies; preparing fact and technical expert witnesses; drafting a wide range of motions and briefs; and taking and defending depositions. She has particular experience representing pharmaceutical patent holders in litigation arising under the U.S. Hatch-Waxman Act and regularly advises on enforcement strategy in high stakes matters involving Japanese parties.
Chiaki frequently lectures on intellectual property issues affecting Japanese companies and their global businesses. She also participates in local professional associations, such as the Licensing Executives Society of Japan (LESJ). Chiaki has been recognized by Intellectual Asset Management (IAM) for her practice in Japan and named in Best Lawyers: Ones to Watch in Japan.
Senju Pharmaceutical Co.; Bausch + Lomb v. Lupin Ltd.
Represented Senju and Bausch + Lomb in Hatch-Waxman patent infringement litigation concerning multiple ANDAs for generic versions of Prolensa®. Secured a permanent injunction against generic defendants.
1:14-cv-00667, -04149; 1:15-cv-00335; 1:16-cv-01097, D.N.J., Judges Goodman, Shipp, Simandle, Williams
Secured a permanent injunction against generic defendants on behalf of Bausch + Lomb, Mitsubishi Tanabe, Ube, and Senju in Hatch-Waxman patent infringement litigation concerning multiple ANDAs for generic versions of opthalmic drug Bepreve®.
1:14-cv-01325, D.N.J., Judges Arpert, Hillman, Schneider, Shipp
Successfully represented Bausch & Lomb and Eye Therapies in a Hatch-Waxman patent infringement litigation and parallel PTAB challenges concerning an ANDA for generic versions of over-the-counter Lumify® ocular drops. The cases settled favorably for our clients.
3:21-cv-16766, D.N.J., Judges Kirsch, Singh
IPR2022-00146, PTAB, Judges Hulse, New, Pollock
IPR2024-00467, PTAB, Judges Flax, Pollock, Yang
IPR2022-00142, PTAB, Judges Flax, Hulse, New, Pollock
Mitsubishi Tanabe Pharma Corporation v. Shanghai Auzone Biological Technology Co., Ltd et al.
Representing Mitsubishi Tanabe Pharma in litigation matters related to Radicava ORS (edaravone) used to treat patients with amyotrophic lateral sclerosis (ALS).
2:25-cv-03326, D.N.J., Judge Cecchi
1:23-cv-00759, D. Del., Judges Burke, Connolly, Hall
1:24-cv-01423, D. Del., Judge Hall
1:24-cv-00549, D. Del., Judge Hall
Commercial Copy Innovations, Inc. v. Mimaki USA, Inc. et al.
8:17-cv-00437, C.D. Cal., Judges Scott, Selna
Dow Pharmaceutical Sciences, Inc. v. Tolmar, Inc.
2:15-cv-07971, D.N.J., Judges Bongiovanni, Chesler, Waldor
Event
Evolving U.S. Patent Strategies: AI Technological Innovation, Challenges in the Chemical and Pharmaceutical Sectors, NPE Litigation, and the Latest Trends in NPE Litigation and at the PTAB Evolving U.S. Patent Strategies: AI Technological Innovation, Challenges in the Chemical and Pharmaceutical Sectors, NPE Litigation, and the Latest Trends in NPE Litigation and at the PTAB
October 30, 2025
Tokyo
Seminar
Evolving Patent Strategies: Recent PTAB Trends, AI Challenges, and Biotech Innovations Evolving Patent Strategies: Recent PTAB Trends, AI Challenges, and Biotech Innovations
May 22, 2025
Tokyo
Hybrid Seminar
Japan Agency for Medical Research and Development Training Japan Agency for Medical Research and Development Training
February 25, 2025
Tokyo
“Chiaki Kobayashi [is] a key adviser in the chemical, biotechnology and pharmaceutical fields, with extensive experience in prosecution, post-grant proceedings and complex litigation.”
Intellectual Asset Management Patent 1000
"Chiaki Kobayashi shines at prosecution, litigation and counselling, especially when it comes to biotechnology and pharmaceuticals. Among her professional highlights is securing a permanent injunction against generics."
Intellectual Asset Management Patent 1000
“Chiaki Kobayashi [is] a key adviser in the chemical, biotechnology and pharmaceutical fields, with extensive experience in prosecution, post-grant proceedings and complex litigation.”
Intellectual Asset Management Patent 1000
"Chiaki Kobayashi shines at prosecution, litigation and counselling, especially when it comes to biotechnology and pharmaceuticals. Among her professional highlights is securing a permanent injunction against generics."
Intellectual Asset Management Patent 1000
Award/Ranking
Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked
May 28, 2026
Intellectual Asset Management (IAM)Award/Ranking
50 Finnegan Attorneys Ranked in the 2025 IAM Patent 1000 50 Finnegan Attorneys Ranked in the 2025 IAM Patent 1000
June 2, 2025
Intellectual Asset Management (IAM)Award/Ranking
46 Finnegan Attorneys Ranked in 2024 IAM Patent 1000 46 Finnegan Attorneys Ranked in 2024 IAM Patent 1000
June 6, 2024
Intellectual Asset Management (IAM)Press Release
Finnegan Receives Top Rankings from Intellectual Asset Management; 46 Attorneys Ranked Finnegan Receives Top Rankings from Intellectual Asset Management; 46 Attorneys Ranked
June 30, 2023
Intellectual Asset Management (IAM)Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.